Failure of successful renal transplant to produce appropriate levels of 1,25-dihydroxyvitamin D
Authors:
- 24 October 2006
- journal article
- research article
- Published by Springer Nature in Osteoporosis International
- Vol. 18 (3) , 363-368
Abstract
Introduction Bone metabolism disturbances following renal transplantation (RT) are complex and multifactorial in origin. Abnormalities in 1,25-dihydroxyvitamin D levels in RT patients under treatment at our Bone Center prompted this retrospective study. Methods Parameters of vitamin D metabolism were compared in RT patients and a cohort of patients with primary hyperparathyroidism (PHTP) who mimicked the hyperparathyroid state of the RT patients. Thirty-one RT recipients (from 300 reviewed) matched our inclusion criteria with a stable graft function for more than 1 year and a glomerular filtration rate (GFR) >50 mL/min per 1.73 m2 (Group A); these were compared with 42 consecutive patients with PHTP who had been referred to the same Bone Center for treatment for over 1 month (Group B). Statistical analysis included the chi-square or Fisher’s exact tests for categorical data and the Wilcoxon rank sum test for quantitative measures. Results The mean (±SD) 1,25-dihydroxyvitamin D level was significantly lower (p < 0.001) in Group A patients (29.8 ± 16.2) than in Group B patients (70.2 ± 25.9) despite non-significant differences in the levels of parathyroid hormone (PTH) (mean: 184.0 vs.101.1;p < 0.29), phosphorus (mean: 3.2 vs. 3.1; p < 0.3) and 1,25-vitamin D (mean: 19.5 vs. 25.2; p < 0.06). Group A patients had lower levels (p < 0.05) of mean serum calcium and calculated GFR (9.3 mg/dL, 65.7 mL/min) than Group B patients (10.6 mg/dL, 97.6 mL/min). 1,25-Dihydroxyvitamin D significantly correlated with calcium (p < 0.001), 25-vitamin D (p < 0.005) and GFR (p < 0.001) in both groups, but there was a notable lack of association between 1,25-dihydroxyvitamin D and PTH (p < 0.64) or phosphorus (p < 0.26) in Group A patients. In this group, 1,25-dihydroxyvitamin D was not influenced by the type of immunosuppresion regimen (p < 0.06), use of biphosphonates (p < 0.73), presence of diabetes (p < 0.59), menopause in women (p < 0.08), season (p < 0.43) or race (p < 0.31). Our data indicate that 1,25-dihydroxyvitamin D metabolism remains disturbed for a considerable time after successful RT, with the result that the level of 1,25-dihydroxyvitamin D in RT patients is lower despite physiological signals that should stimulate its production. Our analysis of many clinical variables was unable to elucidate the underlying mechanism(s) for this disturbance. Conclusion Successful RT may not produce appropriate levels of 1,25-dihydroxyvitamin D commensurate to the elevated levels of PTH. This abnormality along with sustained hyperparathyroidism may contribute to bone loss following transplantation.Keywords
This publication has 37 references indexed in Scilit:
- Prevention of chronic allograft nephropathy with vitamin D*Transplant International, 2005
- Regulation of PTH synthesis and secretion relevant to the management of secondary hyperparathyroidism in chronic kidney diseaseKidney International, 2005
- Interventions for preventing bone disease in kidney transplant recipients2005
- Pathogenesis of parathyroid dysfunction in end-stage kidney diseasePediatric Nephrology, 2004
- Similar risk profiles for post-transplant renal dysfunction and long-term graft failure: UNOS/OPTN database analysisKidney International, 2004
- Treatment with intermittent calcitriol and calcium reduces bone loss after renal transplantationKidney International, 2004
- Hyperparathyroidism and long‐term bone loss after renal transplantationClinical Transplantation, 2003
- Bone mineral density changes within six months of renal transplantationTransplantation, 2003
- The Effects of Vitamin D Receptor Polymorphism on Secondary Hyperparathyroidism and Bone Density After Renal TransplantationJournal of Bone and Mineral Research, 2002
- PREVENTION OF OSTEOPOROSIS AFTER CARDIAC TRANSPLANTATIONTransplantation, 1999